NCT03183674 (OxytocinASD) is a Phase 1 clinical trial of Oxytocin in Autistic Disorder, sponsored by University of Sao Paulo General Hospital.

Who is sponsoring NCT03183674?

NCT03183674 is sponsored by University of Sao Paulo General Hospital.

What drugs are being tested in NCT03183674?

Interventions in NCT03183674: Oxytocin, placebo.

What condition does NCT03183674 study?

NCT03183674 studies Autistic Disorder.

Is NCT03183674 still recruiting?

NCT03183674 is currently completed. Last updated 28 October 2019.

Last reviewed 2019-10-28 · How we verify

NCT03183674: OxytocinASD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxytocin in Spectrum Autism Disorders

Completed Phase 1 Last updated 28 October 2019

What this trial tests

Phase 1 trial testing Oxytocin in Autistic Disorder in 80 participants. Completed in 15 May 2018.

Timeline

15 July 2016

Primary endpoint
20 July 2017

15 May 2018

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	80
Start date	15 July 2016
Primary completion	20 July 2017
Estimated completion	15 May 2018
Sites	1 location across Brazil

Drugs / interventions tested

Oxytocin (OXYTOCIN) — full drug profile →
placebo

Conditions studied

Autistic Disorder — all drugs for Autistic Disorder →

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 3 to 16, any sex, with Autistic Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observe effects of oxytocin on individuals with autism spectrum disorder

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents.
Frye RE. · · 2018 · cited 98× · PMID 30105528 · DOI 10.1007/s40263-018-0556-y
Autism spectrum disorder and the role of nuclear hormone receptors: insights and therapeutic implications.
Chintalapally S, Rajanala K, Upadhyay A. · · 2025 · PMID 41245836 · DOI 10.3389/fnins.2025.1655348

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07188207 — Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section · NA · not yet recruiting
NCT06968481 — Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage · Phase 2 · not yet recruiting
NCT07265180 — Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison · NA · recruiting
NCT07119398 — Oxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM · Phase 4 · recruiting

Other recruiting trials for Autistic Disorder

Currently open trials in the same condition.

NCT05910502 — Project AFECT (Autism Family Empowerment Coaching and Training Program) · NA · active not recruiting
NCT06227780 — Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders · NA · recruiting
NCT05176808 — Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD) · NA · recruiting

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183674 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
Last refreshed: 28 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing